| Literature DB >> 34910747 |
Catherine Blake1, Jodi A Flaws2.
Abstract
BACKGROUND: The manual processes used for risk assessments are not scaling to the amount of data available. Although automated approaches appear promising, they must be transparent in a public policy setting.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34910747 PMCID: PMC8673667 DOI: 10.1371/journal.pone.0260712
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Total target outcome mentions in the collection (regardless of directionality).
| Abstracts that mention an outcome | Total outcome mentions | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anywhere | Result or Conclusion Section | Anywhere | Result or Conclusion Section | ||||||||||||||||||||
| ID | Chemical Name | Total | Prolif | % | Death | % | Cell | % | Prolif | % | Death | % | Cell | % | Prolif | Death | Cell | Prolif | % | Death | % | Cell | % |
| 1 | 1,3-Butadiene | 3,493 | 136 | 3.9 | 93 | 2.7 | 595 | 17.0 | 104 | 76.5 | 79 | 84.9 | 455 | 76.5 | 243 | 297 | 2,507 | 168 | 69.1 | 196 | 66.0 | 1,364 | 54.4 |
| 2 | 4-Aminobiphenyl | 770 | 35 | 4.5 | 10 | 1.3 | 252 | 32.7 | 27 | 77.1 | 10 | 100.0 | 183 | 72.6 | 56 | 17 | 848 | 39 | 69.6 | 16 | 94.1 | 455 | 53.7 |
| 3 | 5-Azacytidine | 6,501 | 1,403 | 21.6 | 902 | 13.9 | 5,638 | 86.7 | 1,091 | 77.8 | 737 | 81.7 | 4,808 | 85.3 | 2,330 | 2,326 | 33,846 | 1,554 | 66.7 | 1,480 | 63.6 | 18,625 | 55.0 |
| 4 | Arsenic | 22,496 | 1,511 | 6.7 | 1,933 | 8.6 | 6,235 | 27.7 | 1,211 | 80.1 | 1,699 | 87.9 | 5,075 | 81.4 | 2,825 | 6,910 | 29,161 | 1,928 | 68.2 | 4,315 | 62.4 | 16,372 | 56.1 |
| 5 | Asbestos | 7,780 | 672 | 8.6 | 332 | 4.3 | 2,851 | 36.6 | 550 | 81.8 | 264 | 79.5 | 2,289 | 80.3 | 1,210 | 877 | 13,339 | 846 | 69.9 | 556 | 63.4 | 7,612 | 57.1 |
| 6 | Benzo-a-pyrene | 12,160 | 988 | 8.1 | 585 | 4.8 | 5,382 | 44.3 | 827 | 83.7 | 516 | 88.2 | 4,353 | 80.9 | 1,727 | 1,748 | 27,239 | 1,249 | 72.3 | 1,187 | 67.9 | 15,612 | 57.3 |
| 7 | Bisphenol A | 12,946 | 829 | 6.4 | 416 | 3.2 | 3,075 | 23.8 | 680 | 82.0 | 351 | 84.4 | 2,422 | 78.8 | 1,610 | 1,015 | 13,981 | 1,087 | 67.5 | 676 | 66.6 | 7,534 | 53.9 |
| 8 | Cadmium | 40,300 | 1,711 | 4.2 | 1,717 | 4.3 | 11,751 | 29.2 | 1,426 | 83.3 | 1,487 | 86.6 | 9,652 | 82.1 | 2,681 | 5,455 | 49,993 | 1,989 | 74.2 | 3,578 | 65.6 | 29,794 | 59.6 |
| 9 | Chloroform | 18,987 | 667 | 3.5 | 488 | 2.6 | 4,500 | 23.7 | 522 | 78.3 | 412 | 84.4 | 3,432 | 76.3 | 1,427 | 1,281 | 15,273 | 840 | 58.9 | 846 | 66.0 | 8,892 | 58.2 |
| 10 | Cyclosporine | 37,290 | 4,090 | 11.0 | 3,309 | 8.9 | 18,685 | 50.1 | 3,085 | 75.4 | 2,644 | 79.9 | 14,450 | 77.3 | 7,226 | 11,172 | 90,912 | 4,774 | 66.1 | 6,749 | 60.4 | 49,422 | 54.4 |
| 11 | Dichloroacetate | 986 | 152 | 15.4 | 183 | 18.6 | 469 | 47.6 | 120 | 78.9 | 143 | 78.1 | 396 | 84.4 | 279 | 472 | 2,512 | 187 | 67.0 | 274 | 58.1 | 1,309 | 52.1 |
| 12 | Diethylnitrosamine | 4,233 | 1,174 | 27.7 | 530 | 12.5 | 2,884 | 68.1 | 920 | 78.4 | 455 | 85.8 | 2,228 | 77.3 | 2,330 | 1,286 | 12,275 | 1,465 | 62.9 | 882 | 68.6 | 6,816 | 55.5 |
| 13 | Diethylstilbestrol | 5,596 | 671 | 12.0 | 202 | 3.6 | 2,524 | 45.1 | 534 | 79.6 | 168 | 83.2 | 2,067 | 81.9 | 1,354 | 593 | 11,643 | 917 | 67.7 | 381 | 64.2 | 7,107 | 61.0 |
| 14 | Ethene Oxide | 6,857 | 227 | 3.3 | 76 | 1.1 | 1,400 | 20.4 | 179 | 78.9 | 60 | 78.9 | 1,056 | 75.4 | 348 | 155 | 4,751 | 241 | 69.3 | 95 | 61.3 | 2,606 | 54.9 |
| 15 | Formaldehyde | 50,707 | 3,692 | 7.3 | 2,211 | 4.4 | 22,941 | 45.2 | 2,540 | 68.8 | 1,571 | 71.1 | 17,487 | 76.2 | 6,675 | 5,391 | 101,063 | 3,730 | 55.9 | 2,918 | 54.1 | 58,836 | 58.2 |
| 16 | Fumonisin_B1 | 1,858 | 242 | 13.0 | 430 | 23.1 | 854 | 46.0 | 187 | 77.3 | 381 | 88.6 | 721 | 84.4 | 489 | 1,827 | 4,169 | 315 | 64.4 | 1,147 | 62.8 | 2,403 | 57.6 |
| 17 | Genistein | 10,383 | 2,180 | 21.0 | 1,219 | 11.7 | 7,149 | 68.9 | 1,674 | 76.8 | 1,039 | 85.2 | 6,088 | 85.2 | 4,724 | 4,416 | 39,064 | 2,894 | 61.3 | 2,776 | 62.9 | 21,341 | 54.6 |
| 18 | Irinotecan | 7,057 | 615 | 8.7 | 742 | 10.5 | 2,696 | 38.2 | 454 | 73.8 | 602 | 81.1 | 1,883 | 69.8 | 1,026 | 2,054 | 11,644 | 648 | 63.2 | 1,272 | 61.9 | 6,055 | 52.0 |
| 19 | Methylene Chloride | 10,861 | 343 | 3.2 | 237 | 2.2 | 1,720 | 15.8 | 272 | 79.3 | 210 | 88.6 | 1,295 | 75.3 | 657 | 737 | 5,619 | 394 | 60.0 | 462 | 62.7 | 3,071 | 54.7 |
| 20 | Nafenopin | 261 | 85 | 32.6 | 50 | 19.2 | 179 | 68.6 | 67 | 78.8 | 47 | 94.0 | 159 | 88.8 | 218 | 356 | 914 | 125 | 57.3 | 232 | 65.2 | 583 | 63.8 |
| 21 | Okadaic Acid | 5,430 | 827 | 15.2 | 767 | 14.1 | 4,208 | 77.5 | 617 | 74.6 | 611 | 79.7 | 3,655 | 86.9 | 1,552 | 2,925 | 21,648 | 999 | 64.4 | 1,771 | 60.5 | 12,890 | 59.5 |
| 22 | Phenobarbital | 16,667 | 845 | 5.1 | 547 | 3.3 | 4,089 | 24.5 | 684 | 80.9 | 458 | 83.7 | 3,219 | 78.7 | 1,641 | 1,435 | 16,635 | 1,113 | 67.8 | 990 | 69.0 | 9,927 | 59.7 |
| 23 | Pyridine | 186,580 | 12,363 | 6.6 | 9,592 | 5.1 | 60,982 | 32.7 | 9,517 | 77.0 | 7,814 | 81.5 | 47,604 | 78.1 | 21,634 | 27,705 | 256,284 | 14,196 | 65.6 | 17,242 | 62.2 | 140,394 | 54.8 |
| 24 | Styrene | 16,780 | 719 | 4.3 | 280 | 1.7 | 3,872 | 23.1 | 568 | 79.0 | 226 | 80.7 | 3,113 | 80.4 | 1,222 | 659 | 18,704 | 819 | 67.0 | 406 | 61.6 | 10,040 | 53.7 |
| 25 | Sulindac | 1,444 | 300 | 20.8 | 383 | 26.5 | 703 | 48.7 | 240 | 80.0 | 325 | 84.9 | 594 | 84.5 | 669 | 1,490 | 3,453 | 420 | 62.8 | 865 | 58.1 | 1,975 | 57.2 |
| 26 | TCDD | 11,621 | 897 | 7.7 | 471 | 4.1 | 4,481 | 38.6 | 734 | 81.8 | 397 | 84.3 | 3,676 | 82.0 | 1,668 | 1,398 | 21,240 | 1,154 | 69.2 | 892 | 63.8 | 12,442 | 58.6 |
| 27 | Thiobenzamide | 118 | 7 | 5.9 | 13 | 11.0 | 24 | 20.3 | 7 | 100.0 | 9 | 69.2 | 20 | 83.3 | 13 | 21 | 61 | 11 | 84.6 | 16 | 76.2 | 43 | 70.5 |
| 482,314 | 36,106 | 7.5 | 26,900 | 5.6 | 174,110 | 36.1 | 27,810 | 77.0 | 22,020 | 81.9 | 137,550 | 79.0 | 65,393 | 81,346 | 781,475 | 42,450 | 64.9 | 50,462 | 62.0 | 438,139 | 56.1 | ||
Fig 1Search process used to identify MEDLINE abstracts for each of the 27 chemicals (see S1 Appendix for the complete search strings).
Fig 2Cell proliferation outcome [41].
Fig 3Partial view of the unified medical language system showing the Medical Subject Heading (MeSH) showing that apoptosis is a type of Regulated Cell Death, which is in turn a type of Cell Death.
Image courtesy of the U.S. National Library of Medicine.
Fig 4Unified Medical Language System (UMLS) showing context for the semantic type cell.
Image courtesy of the U.S. National Library of Medicine.
Cell proliferation example showing how claims and outcomes are aligned with the direction of evidence.
| Claim | Out-come | Noun Phrase | Non-Noun Phrase | Con-clusion | |
|---|---|---|---|---|---|
| ^ | … | Support | |||
| - | … the short-term | … | Neutral | ||
| v | … directly | … | Refute | ||
| ¬ | ^ | … | Negated Support | ||
| ¬ | - | … had | … had | Negated Neutral | |
| ¬ | v | … did | Negated Refute | ||
| ^ | ¬ | … MPP(+)- | … | Refute | |
| - | ¬ | A strong synergistic | … | Neutral | |
| V | ¬ | … | … to | Support | |
| ¬ | ^ | ¬ | PQ did | … did | Negated Refute |
| ¬ | - | ¬ | … had | … had | Negated Neutral |
| ¬ | V | ¬ | … did | … | Negated Support |
The first column captures the negation (¬) and the polarity (^ depicts support,—depicts neutral, and v depicts refuting evidence) of the relationship and the second column captures if the outcome is negated. PMIDs are shown in parenthesis.
Claim vs abstract totals for 3 example thiobenzamide (chemical 27) abstracts.
| ID | Claim Counts | Abstract Counts |
|---|---|---|
| 1 | Support | 1 support for abstract 1 |
| 1 | Support | |
| 2 | Support | 1 support for abstract 2 |
| 2 | Support | |
| 2 | Refute | 1 refute for abstract 2 |
| 2 | Neutral | 1 neutral for abstract 2 |
| 3 | Support | 1 support for abstract 3 |
| 3 | Support |
Fig 5Claims concerning cell proliferation and cell death reported in [4] showing the entire collection (All), abstracts that were marked as relevant (Ann) and abstracts that were not manually annotated as relevant (NotAnn) from [4], where 5A shows abstract frequencies and 5B shows claim frequencies.
Twenty most frequent lemmatized outcome expressions for cell proliferation and cell death, where * depicts negation and depicts a non-noun phrase.
| Cell Proliferation | Abs | Freq | Cell Death | Abs | Freq | ||
|---|---|---|---|---|---|---|---|
| cell proliferation | 4,755 | 6,482 | apoptosis | 11,451 | 23,132 | ||
| cell growth | 2,114 | 2,576 | cell death | 3,852 | 5,545 | ||
| increase_cell | 1,057 | 1,120 | necrosis | 1,599 | 2,122 | ||
| * | antiproliferative effect | 797 | 983 | cell apoptosis | 1,200 | 1,438 | |
| * | antiproliferative activity | 700 | 949 | cell cycle arrest | 901 | 1,124 | |
| proliferate_cell | 620 | 690 | apoptotic cell death | 842 | 1,019 | ||
| proliferate_cell nuclear antigen | 589 | 705 | apoptotic cell | 819 | 1,081 | ||
| cellular proliferation | 589 | 685 | tumor necrosis | 813 | 864 | ||
| lymphocyte proliferation | 274 | 354 | program cell death | 475 | 588 | ||
| mitotic index | 266 | 352 | apoptotic effect | 333 | 395 | ||
| tumor cell proliferation | 247 | 284 | apoptosis induction | 271 | 308 | ||
| * | loss_dopaminergic neuron | 235 | 264 | * | antiapoptotic effect | 237 | 310 |
| t cell proliferation | 207 | 285 | neuronal cell death | 235 | 298 | ||
| cellular accumulation | 187 | 224 | apoptotic | 233 | 249 | ||
| increase_cell viability | 177 | 184 | arrest_cell cycle | 220 | 235 | ||
| * | loss_cell viability | 166 | 182 | proapoptotic effect | 219 | 248 | |
| growth_cell | 163 | 170 | arrest_cell | 210 | 235 | ||
| hepatocyte proliferation | 162 | 239 | kill_cell | 208 | 227 | ||
| * | cell loss | 153 | 176 | neuronal apoptosis | 197 | 278 | |
| * | cell growth inhibition | 145 | 161 | acute tubular necrosis | 190 | 240 | |
Fig 6Cell proliferation claims from results or conclusions sentences showing [A] total abstracts and [B] total claims.
Fig 8General cell claims from results or conclusions sentences showing [A] total abstracts and [B] total claims.
Fig 7Cell death claims from results or conclusions sentences showing [A] total abstracts and [B] total claims.
Fig 9The number of genistein abstracts that report cell proliferation is greater than the number that report cell death (A); however, more claims refute that cell proliferation increases, whereas more claims support an increase in cell death.
Conclusion based on [A] the number of abstracts that mention the target outcome [B] the number of abstracts that include at least 1 claim where the target outcome has increased, and [C] the number of claims where the target outcome has increased.
Data for [B] and [C] consider only the result or conclusion sentences (either actual or estimated).
| [A] Retrieved abstracts | [B] Abstracts with > = 1 support claim | [C] Total support claims | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | Number | % | Number | % | |||||||||||
| ID | Prolif | Death | Concl | Prolif | Death | Concl | Prolif | Death | Concl | Prolif | Death | Concl | Prolif | Death | Concl |
| 1 | 104 | 79 | Prolif | 20 | 43 | Death | 43.5 | 84.3 | Death | 23 | 76 | Death | 33.3 | 63.3 | Death |
| 2 | 27 | 10 | Prolif | 5 | 5 | Death | 55.6 | 83.3 | Death | 6 | 6 | Death | 50.0 | 66.7 | Death |
| 3 | 1,091 | 737 | Prolif | 171 | 443 | Death | 27.0 | 83.9 | Death | 198 | 723 | Death | 23.0 | 71.2 | Death |
| 4 | 1,211 | 1,699 | Death | 222 | 1,156 | Death | 32.8 | 86.8 | Death | 302 | 2,324 | Death | 28.1 | 70.5 | Death |
| 5 | 550 | 264 | Prolif | 100 | 132 | Death | 43.1 | 79.5 | Death | 133 | 232 | Death | 40.5 | 61.4 | Death |
| 6 | 827 | 516 | Prolif | 171 | 269 | Death | 42.9 | 78.4 | Death | 229 | 480 | Death | 38.6 | 61.9 | Death |
| 7 | 680 | 351 | Prolif | 209 | 171 | Prolif | 58.9 | 73.4 | Death | 297 | 268 | Prolif | 51.5 | 61.9 | Death |
| 8 | 1,426 | 1,487 | Death | 214 | 747 | Death | 38.9 | 79.0 | Death | 282 | 1,340 | Death | 35.6 | 59.8 | Death |
| 9 | 522 | 412 | Prolif | 95 | 192 | Death | 35.1 | 74.4 | Death | 116 | 295 | Death | 27.8 | 65.8 | Death |
| 10 | 3,085 | 2,644 | Prolif | 611 | 1,205 | Death | 40.1 | 72.5 | Death | 791 | 2,427 | Death | 32.8 | 54.8 | Death |
| 11 | 120 | 143 | Death | 22 | 89 | Death | 32.4 | 76.1 | Death | 29 | 151 | Death | 28.2 | 68.9 | Death |
| 12 | 920 | 455 | Prolif | 256 | 227 | Prolif | 51.1 | 72.1 | Death | 327 | 353 | Death | 44.0 | 59.8 | Death |
| 13 | 534 | 168 | Prolif | 161 | 74 | Prolif | 59.2 | 66.1 | Death | 204 | 115 | Prolif | 45.0 | 49.8 | Death |
| 14 | 179 | 60 | Prolif | 35 | 15 | Prolif | 44.9 | 71.4 | Death | 44 | 26 | Prolif | 44.0 | 68.4 | Death |
| 15 | 2,540 | 1,571 | Prolif | 306 | 349 | Death | 44.8 | 53.5 | Death | 387 | 497 | Death | 41.2 | 49.3 | Death |
| 16 | 187 | 381 | Death | 42 | 220 | Death | 40.0 | 83.0 | Death | 57 | 505 | Death | 32.4 | 61.9 | Death |
| 17 | 1,674 | 1,039 | Prolif | 486 | 677 | Death | 44.3 | 79.1 | Death | 668 | 1,307 | Death | 35.7 | 62.1 | Death |
| 18 | 454 | 602 | Death | 46 | 387 | Death | 16.2 | 86.4 | Death | 51 | 656 | Death | 13.1 | 72.6 | Death |
| 19 | 272 | 210 | Prolif | 32 | 115 | Death | 21.2 | 79.9 | Death | 40 | 202 | Death | 20.8 | 73.7 | Death |
| 20 | 67 | 47 | Prolif | 29 | 27 | Prolif | 58.0 | 64.3 | Death | 48 | 69 | Death | 58.5 | 43.1 | Prolif |
| 21 | 617 | 611 | Prolif | 130 | 379 | Death | 42.1 | 80.1 | Death | 171 | 771 | Death | 36.7 | 62.0 | Death |
| 22 | 684 | 458 | Prolif | 188 | 172 | Prolif | 60.3 | 64.9 | Death | 254 | 277 | Death | 51.6 | 49.2 | Prolif |
| 23 | 9,517 | 7,814 | Prolif | 1,694 | 4,408 | Death | 35.3 | 76.7 | Death | 2,101 | 7,664 | Death | 29.8 | 60.6 | Death |
| 24 | 568 | 226 | Prolif | 97 | 81 | Prolif | 46.9 | 68.6 | Death | 114 | 100 | Prolif | 41.5 | 57.5 | Death |
| 25 | 240 | 325 | Death | 33 | 237 | Death | 18.2 | 86.5 | Death | 38 | 477 | Death | 12.6 | 67.8 | Death |
| 26 | 734 | 397 | Prolif | 164 | 182 | Death | 45.8 | 70.5 | Death | 213 | 348 | Death | 37.6 | 58.4 | Death |
| 27 | 7 | 9 | Death | 3 | 5 | Death | 100.0 | 71.4 | Prolif | 6 | 5 | Prolif | 75.0 | 62.5 | Prolif |
| 23,558 | 18,284 | Prolif | 5,287 | 11,604 | Death | 38.7 | 76.7 | Death | 7,129 | 21,694 | Death | 33.4 | 61.2 | Death | |